AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Serologies and Lab Testing in Connective Tissue Disease

Description

The transcript discusses serologies and lab testing in connective tissue disease, focusing on various autoimmune conditions such as systemic lupus erythematosus (SLE), dermatomyositis (DM), and systemic sclerosis. Key topics include initial lab evaluations, such as complete blood count (CBC), renal function tests, liver function tests, and urinalysis, emphasizing the importance of testing for indicators like proteinuria. The discussion highlights the significance of antinuclear antibodies (ANA) as a diagnostic tool and details various antibody associations, including anti-dsDNA, anti-Ro, and anti-Smith antibodies, which can correlate with disease severity and specific phenotypes. The health implications of vitamin D levels, complement testing, and the use of autoantibody profiles from specific labs are also mentioned. The presentation further covers therapies for these diseases, detailing the required lab monitoring for medications like methotrexate and azathioprine, including infection screenings. Lastly, the talk addresses vaccination guidelines for immunocompromised patients, stressing the precautions around live vaccines and the importance of timing vaccinations concerning immunosuppressive therapies. Recommendations for managing vaccination and the responses to COVID-19 in immunocompromised individuals were also provided, along with a call for further research on the safety and efficacy of treatments in these populations.

View more

Conclusions

  • Initial laboratory monitoring for cutaneous lupus should include a comprehensive panel assessing renal function, liver function, complete blood count, and urinalysis to evaluate for proteinuria.
  • Autoantibody testing, particularly for ANA, is crucial in diagnosing and monitoring cutaneous lupus and other connective tissue diseases.
  • The interpretation of ANA results should consider the clinical context, as a positive test may occur in healthy individuals.
  • Individuals with ANA-negative systemic lupus erythematosus may have antibodies against cytoplasmic antigens, warranting separate testing for these antibodies when suspected.
  • Complement component testing (C3, C4) can provide insights into disease activity and should be monitored in conjunction with disease progression.
  • Drug-induced lupus can mimic idiopathic lupus; distinguishing features can help guide diagnosis and treatment.
  • Maternity considerations for patients with Ro/SSA antibodies are critical due to the risk of neonatal lupus and congenital heart block, which can be mitigated by administering hydroxychloroquine during pregnancy.
  • Routine monitoring of autoantibodies is not necessary at every visit unless there is a significant change in clinical status or disease activity.
  • JAK inhibitors may present benefits in treatment with quick onset of action but should be prescribed with caution considering patient safety and cancer screening guidelines.
  • Vaccination is recommended for patients on immunosuppressive therapy, but timing and individual risk factors should be evaluated to ensure optimal antibody response.
  • Garg, Merola, Fitzpatrick. Interdisciplinary approaches to Overlap Disorders in Dermatology and Rheumatology. Textbook. 2022.
  • Tan, E.M ., Feltkamp, T.E.W ., Smolen, J.S ., Butcher, B ., Dawkins, R ., Fritzler, M.J ., Gordon, T ., Hardin, J.A ., Kalden, J.R ., Lahita, R.G. and Maini, R.N ., 1997. Range of antinuclear antibodies in "healthy" individuals. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 40(9), pp.1601-1611.
  • Adapted from: Lazar S, Kahlenberg JM. Systemic lupus erythematosus: new diagnostic and therapeutic approaches. Annual Review of Medicine. 2023 Jan 27;74:339-52.
  • Izmirly PM, Llanos C, Lee LA, Askanase A, Kim MY, Buyon JP. Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. Arthritis Rheum. 2010 Apr;62(4):1153-7.
  • Izmirly, P.M ., Costedoat-Chalumeau, N ., Pisoni, C.N ., Khamashta, M.A ., Kim, M.Y ., Saxena, A ., Friedman, D ., Llanos, C ., Piette, J.C. and Buyon, J.P ., 2012. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation, 126(1), pp.76-82.
  • Merola, JF. Drug-Induced Lupus Erythematosus, Chapter in: Schur PH, Massarrotti, E. Clinical Management of Systemic Lupus Erythematosus. Second Edition.
  • Waldman, R ., DeWane, M.E. and Lu, J ., 2020. Dermatomyositis: diagnosis and treatment. Journal of the American Academy of Dermatology, 82(2), pp.283-296.
  • Mecoli, C.A ., Casal-Dominguez, M ., Pak, K ., Pinal-Fernandez, I ., Albayda, J ., Tiniakou, E ., Paik, J.J ., Zahid, U ., Danoff, S.K ., Mammen, A.L. and Casciola-Rosen, L ., 2020. Myositis autoantibodies: a comparison of results from the Oklahoma Medical Research Foundation myositis panel to the Euroimmun research line blot. Arthritis & rheumatology (Hoboken, NJ), 72(1), p.192.
  • Nihtyanova, S.I. and Denton, C.P ., 2010. Autoantibodies as predictive tools in systemic sclerosis. Nature reviews rheumatology, 6(2), pp.112-116.
  • Menzies, D ., Pai, M. and Comstock, G ., 2007. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Annals of internal medicine, 146(5), pp.340-354.